On Chemball

My Chemball

As Supplier

My RFQ Manage Products

As Buyer

My RFQ Post RFQ

My Account

+86-571-8627 3270

Junye Pharmaceutical Co., Ltd

26 YRS

Zhejiang, China

CNY 97.5 Million

500-1000 people

Main Products: Drospirenone / Norethisterone / Norethindrone Acetate / Norethisterone Enanthate / Progesterone / Ulipristal Acetate / Dexamethasone / Dexamethasone Sodium Phosphate / Abiraterone / Finasteride / Hydrocortisone Acetate / Hydrocortisone / Deflazacort / β-Estradiol / Oestradiol 17-Heptanoate / Estradiol Valerate / Medroxyprogesterone Acetate / Hydroxyprogesterone Caproate / 17α-Ethynylestradiol / Estriol / Prednisolone / Prednisolone Acetate / Trilostane / Altrenogest / Eplerenone / Tibolone / Flumethasone / Fulvestrant / Oxandrolone

Zhejiang, China

Contact Supplier

Home Company Profile Contact Us Post Buying Request

Fulvestrant / CAS 129453-61-8

OVERVIEW

Packaging

25 KG/Fibre Drum

Lead Time

14-30 days

REQUEST A QUOTATION

Submit

Get Free Samples

Less than 1KG required

DESCRIPTION

Fulvestrant

CAS:129453-61-8

Molecular formula：C32H47F5O3S

Molecular weight：606.77100

Appearance:White to grayish white crystalline powder

Synopsis：Fluticasone is an intramuscular injection developed by AstraZeneca. It was approved by the food and Drug Administration in April 2002 to treat estrogen receptor positive metastatic breast cancer in postmenopausal women whose disease is still deteriorating after anti estrogen therapy. Many breast cancer cells have estrogen receptor (ER), estrogen can stimulate the growth of such tumors. Fluvestrant is a "pure" estrogen receptor antagonist without partial estrogen like agonistic effect. It inhibits estrogen signal pathway by binding, blocking and down regulating er. It can competitively bind with ER. Its affinity with Er is close to estrogen, 100 times that of tamoxifen. It is the only anti estrogen drug that can be widely used in clinic after tamoxifen fails, Because the drug is endocrine therapy and will not cause common adverse reactions of chemotherapy, it has good patient compliance.

Structural formula:

Typical Properties

Fluticasone is an intramuscular injection developed by AstraZeneca. It was approved by the food and Drug Administration in April 2002 to treat estrogen receptor positive metastatic breast cancer in postmenopausal women whose disease is still deteriorating after anti estrogen therapy. Many breast cancer cells have estrogen receptor (ER), estrogen can stimulate the growth of such tumors. Fluvestrant is a "pure" estrogen receptor antagonist without partial estrogen like agonistic effect. It inhibits estrogen signal pathway by binding, blocking and down regulating er. It can competitively bind with ER. Its affinity with Er is close to estrogen, 100 times that of tamoxifen. It is the only anti estrogen drug that can be widely used in clinic after tamoxifen fails, Because the drug is endocrine therapy and will not cause common adverse reactions of chemotherapy, it has good patient compliance.

CAS No.

129453-61-8

Formula

C32H47F5O3S

Molecular Mass

606.77100

Exact Mass

606.31700

PSA

76.74000

Logp

9.54830

IUPAC

(7R,8R,9S,13S,14S,17S)-13-methyl-7-[9-(4,4,5,5,5-pentafluoropentylsulfinyl)nonyl]-6,7,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthrene-3,17-diol

SMILES

CC12CCC3C(C1CCC2O)C(CC4=C3C=CC(=C4)O)CCCCCCCCCS(=O)CCCC(C(F)(F)F)(F)F

Matter Classification

organic

GET SAMPLE